NRX Pharmaceuticals (NRXP) Enterprise Value (2017 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Enterprise Value of -$6.7 million for Q1 2026, down 21.82% year-over-year from -$8.6 million in Q1 2025, and up 14.07% quarter-over-quarter from -$7.8 million in Q4 2025.
NRX Pharmaceuticals (NRXP) Enterprise Value (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Enterprise Value for 10 consecutive years, with -$6.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 21.82% year-over-year to -$6.7 million; the TTM figure through Mar 2026 stood at -$6.7 million (down 21.82% YoY), while the FY2025 annual figure was -$7.8 million, down 440.33% from the prior year.
- Enterprise Value climbed to -$6.7 million in Q1 2026 per NRXP's latest filing, from -$7.8 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$1.3 million in Q1 2024 and bottomed at -$40.2 million in Q1 2022.
- Historically, Enterprise Value has averaged -$10.8 million across 5 years, with a median of -$7.2 million in 2025.
- Annual changes were most pronounced in 2024 — Enterprise Value jumped 92.01% — and 2025, when it plunged 440.33%.
- NRX Pharmaceuticals' Enterprise Value stood at -$20.1 million in 2022, then soared by 77.09% to -$4.6 million in 2023, then jumped by 68.6% to -$1.4 million in 2024, then slumped by 440.33% to -$7.8 million in 2025, then climbed by 14.07% to -$6.7 million in 2026.
- Business Quant data shows NRXP's Enterprise Value at -$6.7 million in Q1 2026, -$7.8 million in Q4 2025, and -$7.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 2.12 Bn |
| 10 | NRX Pharmaceuticals | 132.83 Mn | 106.13 Mn | 426,000.00 | -26.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.70 Mn |
| Dec 31, 2025 | -7.80 Mn |
| Sep 30, 2025 | -7.18 Mn |
| Jun 30, 2025 | -2.90 Mn |
| Mar 31, 2025 | -5.50 Mn |
| Dec 31, 2024 | -1.44 Mn |
| Sep 30, 2024 | -1.60 Mn |
| Jun 30, 2024 | -1.90 Mn |
| Mar 31, 2024 | -1.32 Mn |
| Dec 31, 2023 | -4.60 Mn |
| Sep 30, 2023 | -8.90 Mn |
| Jun 30, 2023 | -14.97 Mn |
| Mar 31, 2023 | -16.51 Mn |
| Dec 31, 2022 | -20.05 Mn |
| Sep 30, 2022 | -18.25 Mn |
| Jun 30, 2022 | -24.55 Mn |
| Mar 31, 2022 | -40.20 Mn |
| Dec 31, 2021 | -27.61 Mn |
| Sep 30, 2021 | -38.88 Mn |
| Jun 30, 2021 | -13.39 Mn |